

BCBe/04/Neb-Gla/081

Influence of Nebivolol on Ocular Perfusion in patients with Glaucoma and Arterial Hypertension.

This study has been completed. Results will be soon available in the "Results section"

Sponsor: Berlin Chemie AG

Intervention: Nebivolol 5 mg vs Bisoprolol 5 mg

Condition: Arterial Hypertension and glaucoma

Study type & design: Parallel-group, phase IV, double-blind

Main criteria for inclusion: -18 years or older -Stable glaucoma associated with a pathological excavation of the optical nerve head and visual field defects -No other previous eye surgery than cataract surgery -Refractive error between ± 6 and $+ 6$ dpt -Arterial hypertension adequately and stable (≥ 3 months) treated in combination-or mono therapy with a beta-blocker except for current treatment with Nebivolol, Bisoprolol or Carvedilol (blood pressure prior to switch of the antihypertensive medication to the trial medication: < 140 mmHg SBP and < 90 mmHg DBP)

Main criteria for exclusion: -Secondary hypertension -
Untreated heart failure or uncompensated heart failure -
Cardiogenic Shock -Bradycardia (< 50 bpm prior to treatment)
-Hypotension with systolic blood pressure < 90 mmHg